Advanced Cell Technology in Marlborough has received patent protection in China for a vision-loss treatment the company is developing.
The company’s retinal pigment epithelial cell treatment uses human embryonic stem cells to target macular degenerative diseases such as Stagardt’s macular dystrophy and dry age-related macular degeneration.
The company has already received multiple patents in the United States for the treatment, but this is the company’s first Asian patent protection.
The patent from the Chinese State Intellectual Property Office provides protection for the company’s production of human retinal pigment cells, purifying them and preparing them for use in pharmaceutical compositions.
